192 related articles for article (PubMed ID: 28829526)
1. Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet.
Dayno JM; Niebler G; Lawler J; Elhauge T; Lindhardt K
J Opioid Manag; 2017; 13(2):111-124. PubMed ID: 28829526
[TBL] [Abstract][Full Text] [Related]
2. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
Skak N; Elhauge T; Dayno JM; Lindhardt K
J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
[TBL] [Abstract][Full Text] [Related]
3. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
[TBL] [Abstract][Full Text] [Related]
4. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
6. The ALERRT
Cone EJ; Buchhalter AR; Lindhardt K; Elhauge T; Dayno JM
Am J Drug Alcohol Abuse; 2017 May; 43(3):291-298. PubMed ID: 28448223
[TBL] [Abstract][Full Text] [Related]
7. Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets.
Webster LR; Viscusi ER; Brown C; Dayno JM
Curr Med Res Opin; 2018 May; 34(5):893-901. PubMed ID: 29368961
[TBL] [Abstract][Full Text] [Related]
8. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Kinzler ER; Pantaleon C; Aigner S
Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
Webster LR; Pantaleon C; Iverson M; Smith MD; Kinzler ER; Aigner S
Pain Res Manag; 2018; 2018():7276021. PubMed ID: 29849845
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
[TBL] [Abstract][Full Text] [Related]
11. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
Gourlay GK
Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
13. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers.
Heinrich-Nols J; Schug BS; Evers G; Larsimont V; Elze M; Blume HH; Lee LS; Crawford F
Int J Clin Pharmacol Ther; 1999 Mar; 37(3):153-8. PubMed ID: 10190764
[TBL] [Abstract][Full Text] [Related]
15. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
16. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
17. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
Fanelli A; Sorella MC; Ghisi D
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
[TBL] [Abstract][Full Text] [Related]
18. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules.
Johnson F; Wagner G; Sun S; Stauffer J
J Pain; 2008 Apr; 9(4):330-6. PubMed ID: 18201934
[TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]